Actively Recruiting
Lattice Radiation Therapy Versus Conventional Radiation Therapy for the Palliation of Large Tumors
Led by University Health Network, Toronto · Updated on 2026-03-03
148
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are evaluating Spatially Fractionated Lattice Radiotherapy SFRT, also called LATTICE therapy, compared to conventional Radiation Therapy RT for relieving pain and discomfort in patients with large tumors. This phase III randomized trial focuses on whether SFRT leads to a greater reduction in pain at 30 days after treatment, using the International Consensus Pain Response ICPR to measure improvements. The study includes patients with solid tumors larger than 5 cm who require palliative radiation to manage symptoms such as pain and bleeding. The study compares two radiation treatments. One group receives conventional RT using standard techniques with doses ranging from 8Gy in 1 fraction up to 30Gy in 10 fractions. The other group receives SFRT via LATTICE Radiotherapy, which delivers very high doses to specific spots inside the tumor in a lattice pattern while protecting surrounding healthy tissue with lower doses. Treatment plans include 20Gy in 5 fractions with a boost of 67Gy focused on discrete tumor areas. Both therapies are given over several sessions. Participants will undergo assessments including pain questionnaires, opioid use tracking, and tumor imaging before and after treatment. Pain responses are measured at baseline and at 30 days, with follow-up evaluations at 1, 3, and 6 months. Researchers will also monitor treatment-related side effects, tumor response, survival, and health economics. Participants must be able to complete pain diaries and questionnaires and be available for treatment and follow-up visits lasting up to 6 months post-radiotherapy.
CONDITIONS
Brief Title
Lattice Radiation Therapy Versus Conventional Radiation Therapy for the Palliation of Large Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosis of a solid tumor larger than 5 cm from a primary site or metastasis, unsuitable for surgery or definitive radiation
- Hepatocellular carcinoma diagnosed by standard imaging criteria allowed
- Eastern Cooperative Oncology Group (ECOG) status between 0 and 4 within 14 days before randomization
- Requires palliative radiation therapy to a lesion larger than 5 cm confirmed by recent imaging or CT simulation
- Able to understand and provide written consent
- Willing and able to complete pain questionnaires and maintain a pain diary
- Not pregnant, not planning pregnancy or fatherhood within the next 90 days
- Accessible for treatment and follow-up visits and documentation
You will not qualify if you...
- Prior radiotherapy causing substantial overlap with planned treatment area
- Need for urgent surgery before radiation treatment
- Confirmed pregnancy
- Hematologic primary malignancy
- Medical conditions preventing protocol treatment (e.g., connective tissue disorders)
- Tumors pressing on critical central nervous system structures, heart, or causing spinal cord compression
Research Team
J
Jelena Lukovic, MD FRCPC MPH MRMD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here